Evidence map›Paper›PMID 37653055›Full record

ArticleScientific reports2023

Beyond the effects of HIV infection and integrase inhibitors-based therapies on oral bacteriome.

Pablo Villoslada-Blanco, Patricia Pérez-Matute, Emma Recio-Fernández, María Íñiguez, Pilar Blanco-Navarrete, Luis Metola, Valvanera Ibarra, Jorge Alba, María de Toro, José A Oteo

Abstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Pablo Villoslada-BlancoInfectious Diseases, Microbiota and Metabolism Unit, Infectious Diseases Department, Center for Biomedical Research of La Rioja (CIBIR), C/Piqueras 98, CIBIR Building, Third Floor, 26006, Logroño, La Rioja, Spain.
Patricia Pérez-MatuteInfectious Diseases, Microbiota and Metabolism Unit, Infectious Diseases Department, Center for Biomedical Research of La Rioja (CIBIR), C/Piqueras 98, CIBIR Building, Third Floor, 26006, Logroño, La Rioja, Spain. cpperez@riojasalud.es.
Emma Recio-FernándezInfectious Diseases, Microbiota and Metabolism Unit, Infectious Diseases Department, Center for Biomedical Research of La Rioja (CIBIR), C/Piqueras 98, CIBIR Building, Third Floor, 26006, Logroño, La Rioja, Spain.
María ÍñiguezInfectious Diseases, Microbiota and Metabolism Unit, Infectious Diseases Department, Center for Biomedical Research of La Rioja (CIBIR), C/Piqueras 98, CIBIR Building, Third Floor, 26006, Logroño, La Rioja, Spain.
Pilar Blanco-NavarreteCentro de Salud Siete Infantes de Lara, Logroño, La Rioja, Spain.
Luis MetolaInfectious Diseases Department, Hospital Universitario San Pedro, Logroño, La Rioja, Spain.
Valvanera IbarraInfectious Diseases Department, Hospital Universitario San Pedro, Logroño, La Rioja, Spain.
Jorge AlbaInfectious Diseases Department, Hospital Universitario San Pedro, Logroño, La Rioja, Spain.
María de ToroGenomics and Bioinformatics Platform, Center for Biomedical Research of La Rioja (CIBIR), Logroño, La Rioja, Spain.
José A OteoInfectious Diseases, Microbiota and Metabolism Unit, Infectious Diseases Department, Center for Biomedical Research of La Rioja (CIBIR), C/Piqueras 98, CIBIR Building, Third Floor, 26006, Logroño, La Rioja, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral microbiome is the second largest microbial community in humans after gut. Human immunodeficiency virus (HIV) infection triggers an impairment of the immune system which could favour the growth and the colonization of pathogens in the oral cavity, and this dysbiosis has been associated with oral manifestations that worsen the quality of life of these patients. Antiretroviral therapy (ART) could also drive changes in specific oral bacterial taxa associated with such periodontal diseases. Integrase strand transfer inhibitors (INSTIs), therapy of choice in the treatment of naive HIV-patients, are able to reverse the impact of HIV infection on systemic inflammation, gut permeability, and gut bacterial diversity/richness. The objective of this study was to analyse the effects of HIV infection per se and INSTIs on salivary bacteriome composition, taking into consideration other factors such as smoking, that could also have a significant impact on oral microbiome. To accomplish this objective, 26 non-HIV-infected volunteers and 30 HIV-infected patients (15 naive and 15 under INSTIs-regimen) were recruited. Salivary samples were collected to measure lysozyme levels. Oral bacteriome composition was analysed using 16S rRNA gene sequencing. Naive HIV-infected patients showed statistically higher levels of lysozyme compared to controls (p < 0.001) and INSTIs-treated patients (p < 0.05). Our study was unable to detect differences in α nor β-diversity among the three groups analysed, although significant differences in the abundance of some bacterial taxonomical orders were detected (higher abundance in the phylum Pseudomonadota, in the order Acholeplasmatales, and in the genera Ezakiella and Acholeplasma in the naive group compared to controls; and higher abundance in the phylum Mycoplasmatota, in the order Acholeplasmatales, and in the genera Acholeplasma and uncultured Eubacteriaceae bacterium in the INTIs-treated HIV-infected patients compared to controls). These differences seem to be partially independent of smoking habit. HIV infection and INSTIs effects on oral microbiota seem not to be very potent, probably due to the modulation of other factors such as smoking and the greatest outward exposure of the oral cavity.

Indexed as

Anti-HIV AgentsHIV InfectionsHumansIntegrase InhibitorsMuramidaseQuality of LifeRNA, Ribosomal, 16SAnti-HIV AgentsIntegrase InhibitorsMuramidaseRNA, Ribosomal, 16S

Identifiers

PMID37653055
PMCPMC10471600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.